Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

Corporate Governance

Share Trading Policy

1. Introduction and Purpose

1.1: The ordinary shares of Medical Developments International Limited (ASX: MVP) are listed on ASX. MVP aims to achieve the highest possible standards of corporate conduct and governance.

1.2: The purpose of this share trading policy is to ensure compliance with the ASX Listing Rules, and to ensure that Key Management Personnel and their associates are aware of the legal restrictions in dealing in MVP’s shares while such a person is in possession of unpublished price sensitive information concerning MVP.

1.3: The Share Trading Policy regulates dealings by MVP Directors in MVP securities (in this Policy including options and other financial products issued by third parties) and securities of any other entity that may be affected by inside information.

2. Application of the Policy

2.1: This Share Trading Policy applies to the following Designated Persons:

a): Directors ;
b): Officers;
c): Senior Management; and
d): Any employee or consultant who has access to MVP confidential financial and Board documentation.

3. Reasons for the Policy

3.1: The Corporations Act 2001 prohibits persons who are in possession of price sensitive information in relation to particular securities that is not generally available to the public from:

a): Dealing in the securities; or
b): Communicating the information to others who might deal in the securities.

3.2: The objectives of this policy is to ensure that:

a): MVP Staff are aware of the legal restrictions on trading in securities whilst a person is in possession of MVP inside information; and to
b): establish a regime for the Company to prevent inadvertent non compliance.

Pages: 1 2 3 4 5 6 7 8
  • Investors/Media
  • Financial Reports
  • Board of Directors/Management
  • Media Centre
  • Corporate Governance
  • Diversity Policy
  • Share Trading Policy
  • Interviews/Analyst Reports

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter